CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Regulation FD Disclosure

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On November 16, 2019, Caladrius Biosciences, Inc. (the “Company”) issued a press release in connection with its presentation at the American Heart Association Scientific Sessions in Philadelphia, PA on the same date. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.
A copy of a slide presentation that Caladrius Biosciences, Inc. (the “Company”) will use at investor and industry conferences and presentations is attached to this Current Report as Exhibit 99.2 and is incorporated herein solely for purposes of this Item 7.01 disclosure.
The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, except as otherwise expressly stated in such filing.
Item 9.01. Financial Statement and Exhibits.>
CALADRIUS BIOSCIENCES, INC. Exhibit
EX-99.1 2 ex991pressrelease20191118.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019 Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse eventsCLBS16 cell therapy shows promise as a significant advancement in treatment of Coronary Microvascular Dysfunction (CMD),…
To view the full exhibit click here

Story continues below

About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

An ad to help with our costs